Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IDEAYA Biosciences (IDYA) Research & Development (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Research & Development for 7 consecutive years, with $86.6 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 38.22% to $86.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $314.7 million through Dec 2025, up 6.8% year-over-year, with the annual reading at $314.7 million for FY2025, 6.8% up from the prior year.
  • Research & Development hit $86.6 million in Q4 2025 for IDEAYA Biosciences, up from $83.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $140.2 million in Q4 2024 to a low of $11.6 million in Q1 2021.
  • Historically, Research & Development has averaged $44.3 million across 5 years, with a median of $31.4 million in 2023.
  • Biggest five-year swings in Research & Development: surged 261.58% in 2024 and later crashed 38.22% in 2025.
  • Year by year, Research & Development stood at $16.1 million in 2021, then skyrocketed by 53.4% to $24.7 million in 2022, then surged by 56.88% to $38.8 million in 2023, then soared by 261.58% to $140.2 million in 2024, then crashed by 38.22% to $86.6 million in 2025.
  • Business Quant data shows Research & Development for IDYA at $86.6 million in Q4 2025, $83.0 million in Q3 2025, and $74.2 million in Q2 2025.